uh yeah i’d say so <:kewk:929403606950637638>
mine must be buggy lol
I will be joining this soon but will see if we get a bounce in the 2 to 2.50 range. Will watch for now.
Big thanks to gen and fly woman for this challenge. I’m curious about how yall calculate risk reward for these plays, do you have a background in biopharma? Where do you think your “alpha” comes from?
1 Like
Also, do you have specific goals in terms of return? I know conq had the 1k to 1m challenge, I wonder if this will be like 1k to 10k?
I have 20 years experience in Pharma and i believe Flywoman has multiple years experience in biopharma investments, combined with a strong background in finance for another industry.
These are some of the parameter we are looking into:
- Market Opportunity of the Drug
- Value proposition of the drug vs. standard of care.
- Stage of the Catalyst, like NDA, Phase 1, Phase 2, Phase 3, PDUFA
- How robust the clinical study is designed
- interim or previous clinical data, clinical data of similar drugs
- Sentiment related to the Therapeutic Area
- Company Profile (Financials) and clinical research track record of the company
1 Like
The challenge emerged from the biopharma plays Fly and i are doing since over a year and the resulting constant profits. This is for sure not getting rich “over night” challenge, we are looking for constant profits with proper risk management. You will see primary shares plays and a lot of taking profit before the actual catalyst.
2 Likes
I don’t have a specific goal in terms of return other than profitable. I tried having a mini-challenge for myself with my Roth last year and did not hit it (it’s in trading journals on the forum) which made me feel kind of bad, so I rather look at the positive side of things (that I made a 40+% return).
40% YoY is top tier.
Thanks for your insights, its very encouraging to hear about your experiences. Ill be following this challenge closely
2 Likes
@here New Position $ALLK
<a:stockrocket:968516250735095828> 50 Shares at 3.19
Full position, no intent to average down
Phase 2b (Trial: MAVERICK) Phase 2/3Topline results expected by Q1 2024.
Phase 2b (Drug: Lirentelimabin the indication Atopic Dermatitis ) Phase 2 topline data due in Q1 2024.
Medium-term play (3 months)
You need to be available in March and need to able to follow the play in the next 3 months
Transparency: Flywoman and i have already a position in our personal account with a cost basis below 3. We still believe this is a play fitting the challenge, hence we get 50 shares in the Challenge account.
1 Like
A few levels I am watching for ALLK 3/2.90/2.50 support, 3.45/4 resistance. SPRB 2.50/2.25 support, 2.75/3 resistance. Some of this is rounded to the nearest .25 too.
GenFly Portfolio
Reminder: We are playing Data Read outs, these dont have a fixed date, companies often provides gudinace on when they expect the data read out but these are very fluent.
1 Like
Also a simple reminder but valuable one: Set your notifications properly so you can hopefully catch when some of these catalysts workout. I learned this the difficult way a few days ago when HSCS jumped a bit before coming back down. I got pinged but didn’t have my alerts so missed out on a good chance to lock in some profit.
1 Like
Good one ! Often we see the peak in pre-market. If you call out your position we will ping you.
1 Like
ALLK pushing up and looking strong vs market today
Thanks for sharing, I’ll be following as well.
1 Like
-
Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs -
-
Management to host conference call and webcast today at 8:00 am E.T. - trading halted too. Not sure if we going to see it plummet
1 Like
I believe it’s currently halted and will return to trade at 7:30
1 Like